- Conditions
- Acute Rejection, Renal Transplantation
- Interventions
- Campath-1H, rituximab, myfortic
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Interventions
- C1 Esterase Inhibitor, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
- Interventions
- No screening, Regular Screening
- Other
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia
- Conditions
- Graft Dysfunction, Interstitial Fibrosis
- Interventions
- Everolimus, Standard of Care
- Drug · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- doxercalciferol
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Renal Transplantation, Mesenchymal Stem Cells
- Interventions
- Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
- Biological · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Transplant; Complications, CMV
- Interventions
- Letermovir 480 mg once daily, Historical/Control
- Drug · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- End Stage Renal Disease
- Interventions
- Epclusa
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
- Conditions
- Graft Rejection, Kidney Disease
- Interventions
- Alemtuzumab and DSG
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Interventions
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Kidney Transplantation, Renal Transplantation, Grafting, Kidney
- Interventions
- Envarsus XR, Tacrolimus
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Immunosuppression, Transplantation, Kidney
- Interventions
- Voclosporin
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Delayed Graft Function
- Interventions
- Envarsus XR, Tacrolimus
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
- Interventions
- Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Interventions
- Denosumab Inj 60 mg/ml, Placebo
- Drug · Other
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • New York, New York
- Conditions
- Kidney Transplant; Complications, Vascular Diseases, Diabetes
- Interventions
- Dapagliflozin 10mg Tab, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- CMV Disease
- Interventions
- Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- Renal Failure
- Interventions
- LCP-Tacro, Tacrolimus -IR
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Renal Transplant Recipient
- Interventions
- Belatacept, Abatacept
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Organ Transplantation
- Interventions
- Belatacept, Sirolimus, Alemtuzumab
- Drug
- Lead sponsor
- Allan D Kirk, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Renal Transplant
- Interventions
- Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Atlanta, Georgia
- Conditions
- Use of Belatacept in Kidney Transplant Patients
- Interventions
- impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)
- Behavioral
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
- Interventions
- Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more